Pacira BioSciences (PCRX) Shares Outstanding (2010 - 2026)
Pacira BioSciences (PCRX) posted quarterly Shares Outstanding (Entity) of $48.3 million for Q1 2026, up 2.56% year-over-year from $47.1 million in Q1 2025, and up 0.91% quarter-over-quarter from $47.9 million in Q4 2025.
Pacira BioSciences (PCRX) Shares Outstanding (2010 - 2026) Analysis & Trends
Pacira BioSciences' Shares Outstanding (Entity) history runs 17 years deep, the most recent figure standing at $48.3 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 2.56% year-over-year to $48.3 million; the TTM figure through Mar 2026 stood at $48.3 million (up 2.56% YoY), while the FY2025 annual figure was $47.9 million, up 1.73% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $48.3 million, up from $47.9 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $48.3 million in Q1 2026, with the low at $45.1 million in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $46.5 million (2024), against an average of $46.7 million.
- The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Entity) grew 3.07% in 2022, then rose 1.18% in 2024.
- Pacira BioSciences' Shares Outstanding (Entity) stood at $45.9 million in 2022, then increased by 1.2% to $46.5 million in 2023, then gained by 1.28% to $47.1 million in 2024, then grew by 1.73% to $47.9 million in 2025, then climbed by 0.91% to $48.3 million in 2026.
- Business Quant data shows PCRX's Shares Outstanding (Entity) at $48.3 million in Q1 2026, $47.9 million in Q4 2025, and $47.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | 4.44 Bn |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn | 1.17 Bn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn | 417.60 Mn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn | 1.58 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 42.60 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 1.16 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 101.00 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | 499.50 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | 832.44 Mn |
| 10 | Pacira BioSciences | 946.10 Mn | 695.07 Mn | 148.24 Mn | 39.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39.46 Mn |
| Mar 31, 2026 | 40.46 Mn |
| Dec 31, 2025 | 44.57 Mn |
| Sep 30, 2025 | 44.04 Mn |
| Jun 30, 2025 | 45.46 Mn |
| Mar 31, 2025 | 46.28 Mn |
| Dec 31, 2024 | 46.25 Mn |
| Sep 30, 2024 | 46.13 Mn |
| Jun 30, 2024 | 46.17 Mn |
| Mar 31, 2024 | 46.50 Mn |
| Dec 31, 2023 | 46.22 Mn |
| Sep 30, 2023 | 46.42 Mn |
| Jun 30, 2023 | 46.09 Mn |
| Mar 31, 2023 | 45.95 Mn |
| Dec 31, 2022 | 45.52 Mn |
| Sep 30, 2022 | 45.83 Mn |
| Jun 30, 2022 | 45.50 Mn |
| Mar 31, 2022 | 44.87 Mn |
| Dec 31, 2021 | 44.26 Mn |
| Sep 30, 2021 | 44.48 Mn |